D. Shaffer

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

G. Weiss, D. V. Von Hoff, G. Clark, 1992, Anti-cancer drugs.

Phase I study with the DNA sequence-specific agent adozelesin

D. V. Von Hoff, H. Burris, L. Schaaf, 1997, Anti-cancer drugs.

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.

G. Weiss, H. Burris, S. Kalter, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin

Linghua Wang, S. Sidhu, V. Cortez-Retamozo, 2023, bioRxiv.